Clinical Trial Title,,lng,lat,Drug
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,,-1.663439,42.805408,Ivermectin
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,,44.3755185,33.3458996,Ivermectin
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,,-58.4053845,-34.5952261,Ivermectin
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,,77.2120291,28.527476,Ivermectin
Efficacy of Ivermectin in COVID-19,,74.3726762,31.5408931,Ivermectin
Ivermectin and Doxycycine in COVID-19 Treatment,,31.0023174,30.8055576,Ivermectin
Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,,-76.5927362,39.2967385,Ivermectin
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,,30.9991409,30.7924391,Ivermectin
New Antiviral Drugs for Treatment of COVID-19,,31.3589223,31.0409949,Ivermectin
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,,-102.2598747,21.9140456,Ivermectin
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,,-99.133208,19.4326077,Ivermectin
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,,-84.5073963,38.0311683,Ivermectin
A Real-life Experience on Treatment of Patients With COVID 19,,30.9951138,30.8015015,Ivermectin
A Trial of Remdesivir in Adults With Severe COVID-19,,116.4231333,39.942654,Remdesivir
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,,114.2868443,30.6668794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.8441325,33.8520823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.2688043,37.8642168,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.3824274,37.5923049,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.0888289,37.6979825,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.1288238,33.9191479,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.4323129,34.0723526,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-124.1424555,40.7839616,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.2957816,33.7886375,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.293899,34.0984583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.3750021,34.0383728,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.5896036,34.1709445,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.6653709,33.5610031,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.186026,33.897404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.0795279,37.3691517,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.9296357,33.624397,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.2582441,37.8235196,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.6086894,34.0324565,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.86362,33.779675,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.4302294,34.2189257,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.4694322,33.905076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-121.2495341,38.765635,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-121.4694362,38.5713948,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.0951878,32.7913395,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.1251884,32.8297116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.4385597,37.6587814,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.432128,37.7905249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.4429971,37.7824144,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-121.8002512,37.2398041,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.1647052,37.7064867,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-121.9988333,37.3360472,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-118.4796445,34.0307739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.7510442,38.4952463,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.1758669,37.4347593,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-104.8375727,39.7452818,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-104.9335815,39.7319823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-105.086874,39.9699702,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-72.9355663,41.3044229,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-157.9000128,21.3632544,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-87.67369,41.8728476,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-87.6674637,41.8747917,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-87.5987133,41.7886079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-86.1633559,39.7903409,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-91.547979,41.658974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-90.1203167,29.9407282,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-70.276399,43.6531739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-77.0347487,39.0147079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-71.0627826,42.3495371,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-71.1074884,42.3361091,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-71.1049051,42.3397365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-83.7278795,42.283286,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-83.0758102,42.3635022,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-93.2615378,44.9722477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-92.4668833,44.0226255,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-114.0000297,46.8755594,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-72.2729872,43.675364,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-74.0564882,40.8840343,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-74.5952861,40.5683581,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-74.450131,40.4952121,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-74.2125193,40.7100492,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-74.1653704,40.9028953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.8463639,40.855993,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9064045,40.8674032,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.8166244,40.7003783,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.4451577,41.4054443,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.7013309,40.7752276,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.7073828,40.7543773,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.941459,40.8409549,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-73.9542869,40.7643076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-78.9371331,36.0058487,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-81.6060645,41.5052505,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.8767439,45.5394714,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.6127272,45.5275562,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.771627,45.5104546,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.5601232,45.4314461,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-75.1507582,40.0050435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-71.398257,41.851722,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-81.0333789,34.0279493,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-82.4109998,34.818455,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-96.82346,32.7608903,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-96.779048,32.7896805,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-96.8419366,32.8173287,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-97.345412,32.7296877,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-95.399568,29.7106626,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-97.3640532,31.0779405,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-111.8366784,40.7715716,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-77.127521,38.8891114,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-77.2281251,38.8573966,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-77.4299508,37.5408047,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.2052146,48.0000596,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-119.2822234,46.2813864,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.8479904,47.0529957,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.3277093,47.6099974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.3214872,47.6063315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-117.4235336,47.6517794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.4529736,47.2593705,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-122.4478581,47.2453583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,113.261861,23.113169,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.6043875,44.8274249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,3.8623414,43.6301844,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-1.5545498,47.2107575,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,2.3672856,48.8771612,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,2.3827263,48.8488116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,13.3766245,52.5264618,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,6.7922861,51.195064,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.974533,53.5908116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,10.1433156,54.3307016,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,12.375768,51.385368,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,11.599781,48.137976,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,11.57756,48.16945,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.185814,48.815163,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,114.201222,22.378404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,114.1338324,22.3415435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,114.1312557,22.2701076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.638066,45.686107,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,10.233707,45.5614101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,10.0523058,45.1300126,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.2291351,45.4991785,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.1230078,45.5192174,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.197922,45.4588868,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,11.8880771,45.4015071,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,10.3083481,44.8016341,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.1488319,45.1962179,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,9.680999,45.0551613,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,12.4564793,41.866501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,7.6596554,45.0889028,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,139.604878,35.4688457,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,136.9436445,35.1738983,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,139.818798,35.6946101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,128.6051356,35.865942,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,127.0981666,37.6127725,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,127.0056589,37.5672412,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,4.9592096,52.2938961,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,4.4785036,52.1660315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,4.4678541,51.9108848,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,103.7831756,1.2937278,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,103.8348123,1.2804242,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,103.8472413,1.3221188,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.3475567,40.5093672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-8.3879435,43.3444418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,2.142488,41.4283018,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,2.1042573,41.3448959,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,2.1523119,41.3894436,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.983914,43.2820309,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.6951156,40.4876043,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.7190495,40.4389953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.6990068,40.3760381,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.6873977,40.4811633,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-4.4498416,36.7231736,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-5.9803696,37.3618418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,11.9614318,57.6823672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,13.0016352,55.589568,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,18.030376,59.3482904,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,6.1490487,46.1933147,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,8.7908616,46.1688293,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,8.5491775,47.3766158,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,120.3223407,22.6796829,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,120.6804919,24.1572247,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,121.5189863,25.0407391,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.1743487,51.5178108,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-3.1357575,55.9215065,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-4.3402152,55.8628356,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.3582799,53.7442203,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.7995125,54.0423015,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.9641248,53.4093831,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.3195181,51.5751501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.165596,51.553237,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.0938548,51.4681404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-0.1340401,51.5245592,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-2.2294865,53.5178824,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-4.116408,50.4166994,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),,-1.4923035,53.379171,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.8441325,33.8520823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.2688043,37.8642168,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.3824274,37.5923049,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.0888289,37.6979825,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.1288238,33.9191479,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.4323129,34.0723526,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-124.1424555,40.7839616,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.2957816,33.7886375,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.293899,34.0984583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.3750021,34.0383728,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.5896036,34.1709445,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.6653709,33.5610031,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.186026,33.897404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.0795279,37.3691517,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.9296357,33.624397,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.2582441,37.8235196,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.6086894,34.0324565,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.86362,33.779675,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.4302294,34.2189257,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.4694322,33.905076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-121.2495341,38.765635,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-121.4694362,38.5713948,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.0951878,32.7913395,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.1251884,32.8297116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.4385597,37.6587814,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.432128,37.7905249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.4429971,37.7824144,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-121.8002512,37.2398041,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.1647052,37.7064867,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-121.9988333,37.3360472,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-118.4796445,34.0307739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.7510442,38.4952463,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.1758669,37.4347593,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-104.8375727,39.7452818,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-104.9335815,39.7319823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-105.086874,39.9699702,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-72.9223431,41.3163244,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-157.9000128,21.3632544,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-87.67369,41.8728476,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-87.6674637,41.8747917,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-87.5987133,41.7886079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-86.1633559,39.7903409,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-91.547979,41.658974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-90.1203167,29.9407282,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-70.276399,43.6531739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-77.0347487,39.0147079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-71.0627826,42.3495371,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-71.1074884,42.3361091,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-71.1049051,42.3397365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-83.7278795,42.283286,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-83.0758102,42.3635022,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-93.2615378,44.9722477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-92.4668833,44.0226255,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-114.0000297,46.8755594,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-72.2729872,43.675364,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-74.0564882,40.8840343,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-74.5952861,40.5683581,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-74.450131,40.4952121,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-74.2125193,40.7100492,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-74.1653704,40.9028953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.8463639,40.855993,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9064045,40.8674032,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.8166244,40.7003783,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.4451577,41.4054443,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.7013309,40.7752276,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.7073828,40.7543773,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.941459,40.8409549,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-73.9542869,40.7643076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-78.9371331,36.0058487,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-81.6060645,41.5052505,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.8767439,45.5394714,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.6127272,45.5275562,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.771627,45.5104546,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.5601232,45.4314461,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-75.1507582,40.0050435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-71.398257,41.851722,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-81.0333789,34.0279493,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-82.4109998,34.818455,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-96.82346,32.7608903,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-96.779048,32.7896805,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-96.8419366,32.8173287,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-97.345412,32.7296877,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-95.399568,29.7106626,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-97.3640532,31.0779405,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-111.8366784,40.7715716,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-77.127521,38.8891114,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-77.2281251,38.8573966,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-77.4299508,37.5408047,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.2052146,48.0000596,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-119.2822234,46.2813864,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.8479904,47.0529957,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.3277093,47.6099974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.3214872,47.6063315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-117.4235336,47.6517794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.4529736,47.2593705,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-122.4478581,47.2453583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,113.261861,23.113169,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.6043875,44.8274249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,3.8623414,43.6301844,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-1.5545498,47.2107575,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,2.3672856,48.8771612,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,2.3827263,48.8488116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,13.3766245,52.5264618,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,6.7922861,51.195064,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.974533,53.5908116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,10.1433156,54.3307016,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,12.375768,51.385368,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,11.599781,48.137976,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,11.57756,48.16945,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.185814,48.815163,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,114.201222,22.378404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,114.1338324,22.3415435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,114.1312557,22.2701076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.638066,45.686107,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,10.233707,45.5614101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,10.0523058,45.1300126,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.2291351,45.4991785,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.2190716,45.4847912,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.197922,45.4588868,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,11.8909972,45.4042074,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,10.3083481,44.8016341,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.1449014,45.2006198,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,9.680999,45.0551613,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,12.4564793,41.866501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,7.6596554,45.0889028,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,139.604878,35.4688457,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,136.9436445,35.1738983,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,139.818798,35.6946101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,128.6051356,35.865942,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,127.0981666,37.6127725,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,127.0056589,37.5672412,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,4.9592096,52.2938961,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,4.4785036,52.1660315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,4.4678541,51.9108848,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,103.7831756,1.2937278,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,103.8348123,1.2804242,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,103.8472413,1.3221188,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.3475567,40.5093672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-8.3879435,43.3444418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,2.142488,41.4283018,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,2.1042573,41.3448959,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,2.1523119,41.3894436,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.983914,43.2820309,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.6951156,40.4876043,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.7190495,40.4389953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.6990068,40.3760381,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.6873977,40.4811633,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-4.4498416,36.7231736,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-5.9803696,37.3618418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.3762115,39.44351,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,11.9614318,57.6823672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,13.0016352,55.589568,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,18.030376,59.3482904,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,6.1490487,46.1933147,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,8.7908616,46.1688293,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,8.5491775,47.3766158,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,120.3223407,22.6796829,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,120.6804919,24.1572247,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,121.5189863,25.0407391,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.1743487,51.5178108,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-3.1357575,55.9215065,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-4.3402152,55.8628356,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.3582799,53.7442203,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.7995125,54.0423015,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.9641248,53.4093831,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.3195181,51.5751501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.165596,51.553237,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.0938548,51.4681404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-0.1340401,51.5245592,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-2.2294865,53.5178824,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-4.116408,50.4166994,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,,-1.4923035,53.379171,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-86.8064433,33.5019893,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-112.0575015,33.4646895,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-119.7848543,36.742835,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-117.9272201,33.8943451,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-117.2255426,32.8851578,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-118.1872456,33.8079303,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-118.1521448,34.133943,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-117.1605004,32.7515454,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.4347006,37.7683466,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.4578922,37.7627248,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-121.8497581,37.36277,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.3003345,37.5308786,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.7013876,38.4436202,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-118.8832649,34.207655,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-118.0494059,33.9694666,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-104.8319627,39.6901471,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-104.9335815,39.7319823,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-104.9805872,39.6538848,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.629904,41.0344748,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-72.6470639,41.5544714,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-72.7867516,41.6613941,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.5512228,41.0534722,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-77.0507412,38.901261,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.1457302,25.9702499,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.345465,27.4318538,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.1800027,26.0198457,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-81.4451456,30.2626481,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.1414798,25.8130379,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-81.3707509,28.5746404,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-82.53174,27.3187202,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.395574,33.8087433,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.3729609,33.7629065,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.9818414,32.4805568,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.3820071,33.751785,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.5081318,33.4527476,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-81.088798,32.030295,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.9721278,30.8251693,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-87.6994788,41.9753719,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-95.71695,37.2253156,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-87.865238,42.2553365,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-87.8354513,41.860567,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-88.1562162,41.873256,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-86.1442253,39.9821468,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-86.1867987,39.7781772,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-86.0234347,40.0460751,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-91.1075419,30.4040862,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-90.0922393,29.9255899,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-90.1139717,30.0206297,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-89.7704122,30.2838293,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-76.6257057,39.2892017,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-76.612734,39.2930847,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-76.5963089,38.5593911,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-76.6117609,39.3882915,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.1480227,42.3489047,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.1044036,42.3748656,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.1462713,41.7099524,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.1502191,42.709852,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.34085,42.647772,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-70.9541728,42.1757238,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.7920244,42.2730591,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.6558552,42.2650021,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.498856,42.5925502,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.055094,42.3535427,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.0758102,42.3635022,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.742242,43.011833,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-85.580433,42.2855115,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-90.1736583,32.3299207,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-90.2629289,38.6351441,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1123729,40.6681687,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1764487,40.7856535,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.1169561,39.9415299,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.3504719,40.5563582,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.2145035,40.6590205,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9687157,40.9042797,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.86113,40.5314853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.3109106,40.2386315,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.6716971,40.2160069,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.0510031,40.7155777,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.0501141,40.7341106,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9854333,40.2954704,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.4656519,40.7894006,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.0405748,40.2089489,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.459393,40.5014988,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1752203,40.7443458,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1901945,40.7401785,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1316667,40.0769444,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1917012,40.4054853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.1005112,40.9838774,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.3526072,40.7128985,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.010588,40.8827798,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.7520604,40.2359639,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.9275257,39.8426668,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.8037182,42.6558325,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9248154,40.7680385,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.2944672,40.6940791,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.2415629,40.7258337,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9243948,40.816972,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.8913311,40.8529975,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.8458397,40.8492061,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.880041,40.8804291,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9777743,40.691265,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9332436,40.6593818,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.945734,40.6552459,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9425116,40.6996948,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9439771,40.656587,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.0240443,40.60855,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9123577,40.6549713,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9373439,40.678599,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.978424,40.6677145,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9982409,40.6393024,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.0208955,40.6467233,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9428238,40.6187604,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9648753,40.5855566,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-78.8648375,42.9011764,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.554059,40.727212,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.8253356,40.7472479,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.6460742,43.3062687,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.8044537,40.7169469,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9722693,40.746844,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.952559,40.7650229,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9444135,40.7848328,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9430784,40.8414368,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9395087,40.8143104,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.004758,40.7099166,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9634264,40.7646529,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.6305987,40.6519366,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.9357942,41.6943079,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-77.5878398,43.1924948,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.6702617,40.8046832,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.916504,42.8200283,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.086124,40.5847086,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.1162806,40.908827,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-73.6726737,42.7340076,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-79.0514592,35.9039805,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.8208167,35.2098767,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-81.698272,41.4620817,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-83.0168242,39.9941487,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-84.1910137,39.6975779,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-95.919195,36.072651,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.3937008,40.6089201,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.2685264,39.9271854,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-74.9252443,40.2026571,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.2001349,39.9479816,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.1423534,40.0366347,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.007677,40.4571516,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-79.9607843,40.4420639,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.4355842,41.8346224,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-71.477898,41.705411,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-82.4214367,34.8403716,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-81.1135067,34.006705,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-86.8092799,36.1537953,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-97.7746416,30.2253622,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-96.7614722,32.8796103,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-95.5945083,29.7291522,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-95.1120193,29.5003947,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-101.8921,33.576903,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-97.0944701,32.5683689,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-98.572222,29.5078753,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-111.8574151,40.6862543,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-77.2281251,38.8573966,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-77.540136,37.6042575,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-80.0081915,37.3001642,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.1868308,47.6208557,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-122.3053296,47.6485967,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-88.02212,43.0429926,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,151.2207522,-33.8805454,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,144.9819197,-37.8456704,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,144.95617,-37.7989153,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,11.4041024,47.2692124,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.305467,48.303292,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,16.3507732,48.1741674,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,4.345909,50.8344868,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,3.7261488,51.0243757,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,5.3422505,50.9101853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,3.2657973,50.8006544,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,4.6743355,50.8785917,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,5.5670127,50.5725359,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,4.4390186,50.4307688,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-79.7616899,43.6688351,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-75.7214357,45.3925787,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,33.3770175,35.1275993,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.421015,50.0733909,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.3426023,50.0737696,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.4640562,50.1153757,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,12.5667877,55.6960841,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,24.7010389,59.3983667,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,25.2796514,54.6871555,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,2.425341,48.915811,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-4.5283949,48.4015109,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,3.0914286,45.7592004,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.337097,48.0755629,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,2.4563603,48.6205823,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,2.1706494,48.838653,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,1.9206942,47.8361644,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,0.3849052,46.5589271,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,1.1103553,49.4404649,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.2299565,51.4917894,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,13.7765193,51.0544932,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,6.9890087,51.4364493,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.8394874,48.0058642,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,9.9439393,51.5505609,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,9.8049569,52.3835661,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,8.67066,49.41288,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.3458226,49.3064546,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,12.11875,49.0073861,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,9.953425,49.7943468,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,21.7950459,38.2945759,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,23.0448787,40.6310278,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,21.6087213,47.5328052,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-21.9273956,64.1384022,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-9.6886432,52.2652569,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,35.185261,31.773199,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,34.8817607,32.0791871,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,34.842852,32.04671,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,13.4538759,43.6026491,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,16.86185,41.1120624,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,11.3628626,44.4917102,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,11.2470215,43.8072546,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,8.9696536,44.4079103,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,9.2586677,45.6024956,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.2207009,40.8677625,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,10.395631,43.7217638,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.6742345,45.0413899,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,5.8611812,51.8235728,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,4.2633732,52.0556288,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,19.9530916,50.0619877,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,16.9307591,52.4062862,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,19.0076319,50.1138509,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-9.1425133,38.7222155,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-8.6195355,41.1472269,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-8.6015912,41.1812498,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,26.1139908,44.4552889,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,27.5843775,47.170543,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,21.2554657,48.7078402,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,14.5216619,46.0541576,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,15.6487876,46.5517074,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,2.2378635,41.4810618,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-3.6724986,40.4185038,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-5.8273198,43.3760877,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,2.6459085,39.6075129,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-5.6754372,40.9637872,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-1.969499,43.292855,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-16.2856164,28.4480627,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-4.0348853,39.8715417,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-4.7196729,41.6556947,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-0.9003394,41.6354811,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,8.0600175,47.3890743,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.5830579,47.5621796,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,7.2445793,47.1468069,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,9.5387292,46.8640364,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,6.6424293,46.5249174,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,8.2974611,47.0576832,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-3.1902577,51.5067958,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-0.0588687,51.5178708,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-0.1086417,51.4928419,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-0.1752284,51.426563,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),,-1.4344979,50.9331825,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,,-111.9544986,33.6583608,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,,-81.4451456,30.2626481,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,,-92.4668833,44.0226255,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-117.024154,32.6172649,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-90.1139717,30.0206297,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-93.7608764,32.4807365,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-71.0731311,42.3344959,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-72.6037013,42.1216158,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-74.1752203,40.7443458,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-111.87937,40.778402,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-86.8039601,33.503198,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-117.225354,32.878285,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-118.4466758,34.065656,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-117.8891443,33.7885817,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-122.1402524,37.405063,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-122.1743078,37.4379735,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-121.4567734,38.5561515,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-117.1455806,32.7263636,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-122.4050025,37.7561796,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-118.381347,34.0767527,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-104.8298306,39.7428484,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-104.9904527,39.7265475,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-82.3497282,29.6375743,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-84.278597,33.790841,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-84.3115191,33.8016027,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-87.623185,41.8947452,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-87.672656,41.8705427,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-90.0846281,29.9613085,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-76.625715,39.2889604,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-76.5927362,39.2967385,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-77.0938454,39.0016164,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-77.1043789,39.0025272,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-71.0688334,42.3631542,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-71.7632542,42.2777464,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-93.2311679,44.9711356,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-90.231968,38.633482,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-95.9759165,41.2548549,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-73.8797647,40.8801514,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-73.9740737,40.7493378,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-77.6269403,43.1230503,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-78.9430478,36.0076689,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-76.6745953,40.2643934,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-75.192598,39.9476279,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-86.8004882,36.1424588,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-96.8451734,32.8157077,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-98.4167342,29.4597886,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-94.7786557,29.3113831,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-95.396499,29.7105296,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-98.5753521,29.5074654,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-78.5004851,38.0344004,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-76.3046348,36.8437973,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-122.1786164,47.715878,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-117.4133073,47.6488744,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-122.55207,47.1097586,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,139.716339,35.7016562,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,126.9975506,37.5787082,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-99.1553977,19.2891535,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,-99.1590142,19.2921803,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,103.7834994,1.2922814,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,103.8472413,1.3221188,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,103.9495701,1.3401915,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),,103.7453915,1.3337448,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-113.9839451,51.0789832,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-114.1334883,51.0652154,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-114.0974163,50.9903099,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-113.9518929,50.8819537,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-113.5232015,53.5207634,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-123.0967667,49.2673536,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-123.1280047,49.2806332,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-123.3279138,48.4327191,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-123.4330644,48.4665044,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-79.7743193,43.2218746,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-81.2548309,43.0009154,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-81.2745418,43.0124531,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-81.22543,42.960029,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-75.6478786,45.4007275,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-75.6394863,45.4461659,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-75.7214357,45.3925787,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-75.8076141,45.3349843,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-79.3627441,43.7690968,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-79.3756596,43.7224812,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-79.4052302,43.6534793,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-73.5574486,45.5112735,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-73.6015785,45.4732623,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-71.2107848,46.8152117,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-71.2977055,46.7790343,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,,-71.880256,45.407037,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-86.8039601,33.503198,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-117.225354,32.878285,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-118.4466758,34.065656,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-117.8891443,33.7885817,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.1402524,37.405063,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.1743078,37.4379735,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-121.4567734,38.5561515,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-117.1455806,32.7263636,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.4050025,37.7561796,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-118.381347,34.0767527,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-104.9904527,39.7265475,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-84.278597,33.790841,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-87.623185,41.8947452,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-87.672656,41.8705427,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-90.0846281,29.9613085,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-76.625715,39.2889604,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-76.5927362,39.2967385,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-77.0938454,39.0016164,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-77.1043789,39.0025272,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-71.0688334,42.3631542,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-71.7632542,42.2777464,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-93.2311679,44.9711356,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-90.231968,38.633482,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-95.9759165,41.2548549,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-73.8797647,40.8801514,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-73.9740737,40.7493378,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-77.6269403,43.1230503,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-78.9430478,36.0076689,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-76.6745953,40.2643934,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-75.1928899,39.9470802,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-86.8004882,36.1424588,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-98.4167342,29.4597886,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-94.7786557,29.3113831,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-95.396499,29.7105296,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-98.5753521,29.5074654,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-78.5004851,38.0344004,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-76.3046348,36.8437973,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.1786164,47.715878,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.3182835,47.6588389,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-117.4133073,47.6488744,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-122.55207,47.1097586,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,12.5667877,55.6960841,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,7.1045497,50.7018469,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,6.9170435,50.9236621,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,8.6616969,50.0951726,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,22.9600672,40.629556,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,23.7786871,37.968196,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,139.716339,35.7016562,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,127.1231772,37.3520673,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,126.9975506,37.5787082,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-99.1553977,19.2891535,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-99.1590142,19.2921803,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,103.8472413,1.3221188,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,2.1523119,41.3894436,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,2.2378669,41.4811171,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-0.1182958,50.8193472,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-0.1188545,51.4990946,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-1.6190553,54.9802057,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-1.5192863,53.806748,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),,-1.2188774,51.764391,Remdesivir
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,,10.7274539,59.9287098,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.2558589,49.8728114,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,6.2427775,49.0836738,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,5.9626178,47.2253089,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,-0.6061928,44.829016,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.4517989,48.7980441,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,5.0691471,47.3213803,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,-61.0380384,14.6339646,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3522501,48.8105963,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,5.7453333,45.1988668,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,3.0347031,50.6108999,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,4.8315594,45.7608649,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,3.8504425,43.6315886,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,7.3412062,47.7387331,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,6.192022,48.6852009,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,-1.5543918,47.2120313,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,7.2822826,43.7243711,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3827263,48.8488116,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3650429,48.8370792,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3402667,48.8368937,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3103313,48.829771,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.2740724,48.8389124,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3317094,48.8988449,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,-1.6950482,48.1200595,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.3711375,48.9335315,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,2.4253137,48.843381,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,4.3629634,45.4820275,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,7.7071667,48.5929237,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,1.4369245,43.5995462,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,1.4369245,43.5995462,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,3.1812134,50.743301,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,0.6696853,47.3872732,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,6.1175557,45.9338394,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,6.100888,49.618558,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,,6.1765466,49.6323792,Remdesivir
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.523274,48.9545206,Remdesivir
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.5720537,48.8984523,Remdesivir
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",,-118.2075585,34.0575334,Remdesivir
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",,-118.2048393,34.0613426,Remdesivir
Sarilumab for Patients With Moderate COVID-19 Disease,,-71.1099407,42.3272945,Remdesivir
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),,-46.7104346,-23.6477874,Remdesivir
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,,2.4517989,48.7980441,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,4.8748526,45.7803551,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,10.3083481,44.8016341,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,9.3159735,40.3255781,Remdesivir
Convalescent Plasma Therapy in Severe COVID-19 Infection,,90.3946767,23.739822,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-75.2811942,2.9321351,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0519893,4.7068994,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0345157,4.7413984,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0640042,4.6282546,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.1065512,4.6482242,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0957156,4.6489485,Remdesivir
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,,15.9801721,45.8297653,Remdesivir
Early Short Course Corticosteroids in COVID-19,,-83.0854662,42.3678016,Remdesivir
Study of Open Label Losartan in COVID-19,,-94.6113987,39.05635,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-117.8265049,33.6845673,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-118.4451811,34.068921,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-121.8069487,37.211053,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-77.0368707,38.9071923,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-82.4827429,27.9497028,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-89.6145301,40.7097557,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-90.1528519,29.9840922,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-76.6121893,39.2903848,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-83.0457538,42.331427,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-90.1994042,38.6270025,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-115.1499011,36.2093572,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-78.8662219,35.923193,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-78.8783585,35.0526641,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-75.1533655,39.9383221,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,,-86.8014009,36.1425227,Remdesivir
Efficacy of Tocilizumab on Patients With COVID-19,,-71.067566,42.3626109,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.6489943,-23.5916438,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.6436478,-23.5729864,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.6435635,-23.5690595,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.6419505,-23.5664177,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.638029,-23.562,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.7152547,-23.5999606,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,,-46.6537114,-23.5572749,Tocilizumab
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,,13.5139647,43.6173812,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.6116796,44.9072727,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.846697,45.6219651,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,15.0830304,37.5078772,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,15.0830304,37.5078772,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,16.2486644,39.293416,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.9319865,45.5952076,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9252269,44.647128,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,14.222673,40.8624762,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,12.9070597,43.9074642,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,14.0733013,40.849415,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,12.1902021,44.4100508,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,15.6594798,38.1130568,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,12.5889668,44.0474034,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,12.4285757,41.9319404,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.9856288,45.4521332,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),,10.8394968,45.3474616,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),,7.4247343,46.9472676,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),,6.6424293,46.5249174,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),,8.9606,46.0098198,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),,8.5491775,47.3766158,Tocilizumab
Tocilizumab Treatment in Patients With COVID-19,,-99.1603831,19.2892389,Tocilizumab
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,,15.9801721,45.8297653,Tocilizumab
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,,114.309504,30.552113,Tocilizumab
"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",,-87.6042591,41.7887967,Tocilizumab
"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",,10.1782429,36.8698022,Tocilizumab
A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,,-157.8538531,21.3085481,Tocilizumab
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",,2.174314,41.4136997,Tocilizumab
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,,-73.9634264,40.7646529,Tocilizumab
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,,101.6528322,3.1137086,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.6672675,44.919041,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.4497879,44.7060814,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,8.6214506,44.9152712,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.0523058,45.1300126,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,7.5366136,44.3853584,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,11.6963026,44.7998971,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,11.2476977,43.8072701,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,8.9429838,44.414108,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,8.0119012,43.8802392,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,9.8320678,44.1118233,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.7732402,45.1448334,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,9.145011,45.471875,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,8.621987,45.4420038,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,11.8846965,45.4127245,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.3083481,44.8016341,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,9.7000319,45.0570706,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.4432297,43.7064336,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,7.6649541,45.0524366,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,9.6111994,45.5101004,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,12.2644188,45.6612591,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,12.3197938,45.9873685,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,12.2232083,45.513721,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.9856288,45.4521332,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,,10.9359529,45.5303486,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,,35.1494106,31.7649503,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,,34.5592871,31.6622785,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,,34.7627074,32.0360309,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,,34.842852,32.04671,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-112.0575015,33.4646895,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-110.9461054,32.2410865,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-117.083637,32.633558,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-115.5684684,32.7802257,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-117.0094774,32.7804422,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-117.1960044,33.9121778,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-122.2321344,37.7989017,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-122.1428781,37.7127151,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-72.9338698,41.30323,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-77.0204624,38.9212171,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-80.3176547,25.747314,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-84.9600928,32.5268217,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-94.6113987,39.05635,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-90.1436859,29.9631002,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-93.7034604,32.4284824,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-77.2424097,39.1817574,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-77.0347487,39.0147079,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-83.0758102,42.3635022,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-115.122352,36.114124,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-74.1653704,40.9028953,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-108.2160998,36.7265744,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.8913311,40.8529975,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.9439771,40.656587,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.9456988,40.6552934,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.8857314,40.7451694,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.8166076,40.7551189,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.8166244,40.7003783,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-73.9395087,40.8143104,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-74.9825672,44.6764714,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-75.1507582,40.0050435,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-96.7432104,43.5355194,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,,-88.0706558,43.1751518,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-117.2340135,32.8800604,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-117.0094774,32.7804422,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-118.4423562,34.0642829,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-122.169719,37.4274745,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-104.9910801,39.7282404,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-80.2119928,25.7904064,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-87.6674637,41.8747917,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-87.5987133,41.7886079,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-90.9999851,30.442823,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-72.6037013,42.1216158,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-92.4668833,44.0226255,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-74.0564882,40.8840343,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-74.450131,40.4952121,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-73.9064045,40.8674032,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-78.9371331,36.0058487,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-81.6211125,41.5025982,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-75.1560106,39.9478658,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-95.4006224,29.7077057,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-95.3933462,29.7106406,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-113.5539707,37.0968017,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-111.87937,40.778402,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-122.1786164,47.715878,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-122.3795882,47.667469,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-79.8540916,43.2624646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-79.7743193,43.2218746,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-79.3876181,43.6598777,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-73.5761859,45.513589,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,12.5667877,55.6960841,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,12.470292,55.648779,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,10.3675736,55.3850091,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,12.0903485,55.6361646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-1.4118805,46.6677714,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,1.2357132,45.812311,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,4.8308236,45.7818414,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-1.5545498,47.2107575,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,2.3650429,48.8370792,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,2.3402667,48.8368937,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,0.6803135,47.389633,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,6.7888551,51.1987065,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,9.8049569,52.3835661,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,10.1406978,54.3298132,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,6.9170635,50.9234823,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,11.4699801,48.1106346,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,14.2207009,40.8677625,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,12.4564793,41.866501,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,9.638066,45.686107,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,9.1230078,45.5192174,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,9.2586677,45.6024956,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,9.1488319,45.1962179,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,4.7628566,51.57417,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,5.0789414,52.0249593,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,4.4703037,51.9112533,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,5.1799131,52.0865646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,2.1042573,41.3448959,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,2.142488,41.4283018,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,2.1523119,41.3894436,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-3.6873977,40.4811633,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-3.6951156,40.4876043,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-3.6724986,40.4185038,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-3.6667259,40.4902031,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-4.321016,55.883619,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-1.5528918,53.8025196,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-0.1363551,51.5250834,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-0.1659994,51.5531475,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-0.2343059,51.516825,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-0.1748772,51.4987997,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-2.2301193,53.5184925,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,,-2.3238955,53.487482,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-111.9544986,33.6583608,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-110.9461054,32.2410865,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-117.9272201,33.8943451,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-118.2075585,34.0575334,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-118.2016181,34.0621498,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-73.4222749,41.1117461,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-77.0751693,38.911464,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-81.6634784,30.347113,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-81.4451456,30.2626481,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-87.7327824,41.7217943,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-87.8476325,42.0385102,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-90.1810171,30.0105053,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-76.6257057,39.2892017,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-119.7952114,39.52552,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-74.1653704,40.9028953,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-73.9456988,40.6552934,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-73.8166244,40.7003783,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-73.9357942,41.6943079,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-80.2791958,36.1355052,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-81.6060645,41.5052505,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-83.5429045,41.6686144,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-75.5241629,40.5667553,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-75.1507582,40.0050435,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-80.0040318,40.4425172,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-79.9478413,32.7850493,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-95.399568,29.7106626,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-95.3889518,29.702086,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,,-95.6309922,29.5891707,Tocilizumab
"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",,18.030376,59.3482904,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-117.024154,32.6172649,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-90.1139717,30.0206297,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-93.7608764,32.4807365,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-71.0731311,42.3344959,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-72.6037013,42.1216158,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-74.1752203,40.7443458,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,,-111.87937,40.778402,Tocilizumab
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),,-84.3194393,33.7928615,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.6653306,38.016598,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,20.8424173,39.620779,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,21.7950459,38.2945759,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.7315473,38.014229,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.769038,37.992309,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.7275388,37.9838096,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.75975,37.9836396,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.6653306,38.016598,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.7547649,37.8480872,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.5323004,38.071821,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,NA,NA,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,22.4191254,39.6390224,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,23.7295198,37.9357211,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,22.9586356,40.6372887,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,22.9444191,40.6400629,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,22.9617339,40.6116363,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,,22.9600672,40.629556,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,2.1385079,41.415745,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,2.174314,41.4136997,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,0.6134759,41.62665,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,-3.6951156,40.4876043,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,-3.6776538,40.4327229,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,-3.7156662,40.4894832,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,-0.4033429,39.4907502,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,,-0.393695,39.4524937,Tocilizumab
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,,12.5416785,55.7121556,Tocilizumab
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,,12.326221,55.930868,Tocilizumab
Randomised Evaluation of COVID-19 Therapy,,-1.2151574,51.7516232,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.571717,55.731551,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.8074627,55.7984686,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.5286696,55.7039349,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.8074627,55.7984686,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,30.3609096,59.9310584,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),,30.3609096,59.9310584,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,3.1930172,51.2208468,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.345909,50.8344868,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.265892,50.813446,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.4520234,50.8529013,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.4108109,51.157693,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,5.517904,50.957107,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,3.7217947,51.0601558,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,3.7261488,51.0243757,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,5.3473957,50.9085411,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.3086096,50.8878094,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.2076091,50.477916,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,5.5778565,50.6521064,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,5.5919769,50.6459547,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,4.5609799,50.667795,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,,3.1233251,50.9539257,Tocilizumab
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,,37.6172999,55.755826,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,,1.1232334,41.1443624,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,,2.1941912,41.3838907,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,,-3.6667259,40.4902031,Tocilizumab
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.523274,48.9545206,Tocilizumab
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.5720537,48.8984523,Tocilizumab
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,,51.3435135,35.7091321,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-75.2811942,2.9321351,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0519893,4.7068994,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0345157,4.7413984,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0640042,4.6282546,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.1065512,4.6482242,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0957156,4.6489485,Tocilizumab
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,,2.1523119,41.3894436,Tocilizumab
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,,37.6172999,55.755826,Tocilizumab
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,,-3.6959039,40.4369834,Tocilizumab
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,,-0.3867362,39.4607499,Tocilizumab
Study of Open Label Losartan in COVID-19,,-94.6113987,39.05635,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-6.1486211,36.699219,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-6.1515222,36.5200097,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-4.827745,36.5079652,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-2.4411846,36.8626932,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-6.2782299,36.5089533,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-3.6099419,37.1885496,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-3.6050952,37.1466315,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-6.926967,37.2798933,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-4.4498416,36.7231736,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-4.4780498,36.7183379,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-5.986478,37.4065718,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-5.9803696,37.3618418,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-5.9712578,37.3188416,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,,-5.9691386,37.3816501,Tocilizumab
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,,-77.1043789,39.0025272,Tocilizumab
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,,7.5830579,47.5621796,Tocilizumab
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,,5.3933001,43.2753932,HCQ + Azithromycin
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),,3.8248185,43.6363429,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,,-111.8950267,40.6579289,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,,-111.8421021,40.7649368,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.3036941,40.7637521,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-73.9854333,40.2954704,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.4656519,40.7894006,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.450131,40.4952121,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.4486555,40.4965117,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.1910884,40.7406294,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,-74.3536318,40.7127936,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,,-111.8950267,40.6579289,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,,-111.8421021,40.7649368,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-118.2436849,34.0522342,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-122.3955966,37.7689296,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-82.3248262,29.6516344,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-87.6276182,41.8886599,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-91.1871466,30.4514677,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-76.6121893,39.2903848,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-76.6121893,39.2903848,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-92.3340724,38.9517053,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-79.0558445,35.9131996,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,,-122.3320708,47.6062095,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-38.9404,-12.277271,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-38.4959327,-12.9572223,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-40.8460076,-14.8626279,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-40.8502201,-14.8789474,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-47.8699039,-15.7651574,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-47.9357361,-15.802223,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-40.6296641,-19.5400456,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-43.9441692,-19.9803381,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-44.2578585,-21.1356146,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-51.1606506,-23.3266892,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-43.1876578,-22.913457,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-51.1562243,-29.1611805,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-51.2214794,-30.0309242,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-51.2214794,-30.0309242,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-49.3643241,-28.6744925,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-48.5449549,-27.6011594,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-48.533927,-27.577689,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-48.845416,-26.289832,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-48.5717864,-20.5545292,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.4335116,-23.504914,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.7152547,-23.5999606,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6419505,-23.5664177,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6431081,-23.5674333,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6698263,-23.5571357,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6540085,-23.5969896,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.643593,-23.5975138,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6748267,-23.5849389,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),,-46.6276882,-23.5951605,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,,-46.6322189,-23.6181027,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",,2.4239471,48.9146194,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",,2.2354935,48.8492607,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",,2.3083004,48.9082554,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",,2.3650429,48.8370792,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",,2.3827263,48.8488116,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,,-46.6322189,-23.6181027,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-86.8056842,33.5029685,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-118.4031397,34.0539099,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-117.1658249,32.7555263,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-122.4562335,37.7642347,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-118.2947364,33.8298404,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-104.8420288,39.7426294,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-77.0315469,38.9104557,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-87.668852,41.8735131,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-71.067566,42.3626109,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-74.189656,40.7400804,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-73.9932413,40.7441606,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-73.954897,40.7649151,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-77.6260033,43.1305531,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-79.0469134,35.9049122,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-79.7919754,36.0726354,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-84.4675849,39.1473527,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-81.620474,41.504468,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-83.0306222,40.0068363,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-75.1932137,39.9522188,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-79.960835,40.4443533,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-86.8026551,36.1447034,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-96.8254278,32.744499,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-122.3035199,47.6553351,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,,-66.0522082,18.3966848,HCQ + Azithromycin
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,,35.8749208,32.0044797,HCQ + Azithromycin
"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",,7.7462879,48.5764648,HCQ + Azithromycin
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),,-46.7104346,-23.6477874,HCQ + Azithromycin
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,,-73.6702617,40.8046832,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,9.9101091,57.0386022,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,12.5401313,55.7140142,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,12.5467355,55.7388664,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,12.543775,55.715282,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,12.326221,55.930868,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,10.3675736,55.3850091,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,12.0903485,55.6361646,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,,11.370371,55.400234,HCQ + Azithromycin
Asymptomatic COVID-19 Trial,,-74.450131,40.4952121,HCQ + Azithromycin
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",,2.174314,41.4136997,HCQ + Azithromycin
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),,7.7093834,48.5940073,HCQ + Azithromycin
Azithromycin in Hospitalized COVID-19 Patients,,51.3980673,35.8001144,HCQ + Azithromycin
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,,35.8749208,32.0044797,HCQ + Azithromycin
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,,-17.4641781,14.6947013,HCQ + Azithromycin
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,,-17.1636608,14.7268344,HCQ + Azithromycin
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,,-17.3996674,14.7753661,HCQ + Azithromycin
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,,-0.182401,51.4849533,HCQ + Azithromycin
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,,-0.3243212,51.4736289,HCQ + Azithromycin
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),,-122.5052644,37.782395,HCQ + Azithromycin
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",,-111.9264707,33.5871371,HCQ + Azithromycin
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",,-90.0715323,29.9510658,HCQ + Azithromycin
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,,-84.5073963,38.0311683,HCQ + Azithromycin
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,,-90.0814661,29.960568,HCQ + Azithromycin
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,,14.4378005,50.0755381,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-75.2811942,2.9321351,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0519893,4.7068994,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0345157,4.7413984,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0640042,4.6282546,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.1065512,4.6482242,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,,-74.0957156,4.6489485,HCQ + Azithromycin
A Study of Quintuple Therapy to Treat COVID-19 Infection,,-119.2210602,34.2566277,HCQ + Azithromycin
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),,10.1782429,36.8698022,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,,32.8631625,39.9303672,HCQ + Azithromycin
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,,-75.3775164,6.1406917,HCQ + Azithromycin
Patient Preference Trial for COVID-19 (PPT-COVID),,7.4126981,43.7307715,HCQ + Azithromycin
Bacteriotherapy in the Treatment of COVID-19,,12.5144384,41.9037626,HCQ + Azithromycin
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,,37.6172999,55.755826,HCQ + Azithromycin
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,,-79.8457682,43.2401034,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,,-0.5548297,47.4815099,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,,-1.4118805,46.6677714,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,,0.3849052,46.5589271,HCQ + Azithromycin
Randomised Evaluation of COVID-19 Therapy,,-1.2151574,51.7516232,HCQ + Azithromycin
Hydroxychloroquine for COVID-19,,9.0576448,48.5216364,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-87.6771887,41.8746646,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-90.1203167,29.9407282,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-71.1053991,42.3504997,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-73.9722693,40.746844,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-76.1395979,43.0422979,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-122.3035199,47.6553351,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,,-122.3182835,47.6588389,HCQ + Azithromycin
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,,12.5134687,41.9627606,HCQ + Azithromycin
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,,44.3755185,33.3458996,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,,2.302302,48.7567574,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,,2.4250233,48.9158686,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,,2.4654319,48.7964094,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,,2.3103313,48.829771,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,,2.3327172,48.822009,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.828466,38.0463484,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.6423642,37.9701123,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,25.873962,40.8457193,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.7653267,37.9833862,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.7275388,37.9838096,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.7793555,37.9950485,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,20.8424173,39.620779,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,23.6455378,37.9343508,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,,22.9600672,40.629556,HCQ + Azithromycin
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.523274,48.9545206,HCQ + Azithromycin
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,,2.5720537,48.8984523,HCQ + Azithromycin
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,4.8748526,45.7803551,HCQ + Azithromycin
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,10.3083481,44.8016341,HCQ + Azithromycin
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,,9.3159735,40.3255781,HCQ + Azithromycin